Mary Ann Liebert: Effectiveness of Using SiRNA to Treat Huntington's Disease
July 23, 2024
July 23, 2024
NEW ROCHELLE, New York, July 23 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
In Huntington's disease, the mutant huntingtin gene (HTT) mRNA is retained in the nucleus and forms insoluble clusters. A new study shows that short interfering RNA (siRNA), an oligonucleotide therapeutic strategy that reduces levels of huntingtin mRNA in the cytoplasm, does not lower mutate HTT mRNA expression in the nucleus of mouse brains. The study is published in the peer-review . . .
In Huntington's disease, the mutant huntingtin gene (HTT) mRNA is retained in the nucleus and forms insoluble clusters. A new study shows that short interfering RNA (siRNA), an oligonucleotide therapeutic strategy that reduces levels of huntingtin mRNA in the cytoplasm, does not lower mutate HTT mRNA expression in the nucleus of mouse brains. The study is published in the peer-review . . .